[发明专利]用于治疗癌症的化合物及其制备方法和用途

说明书

技术领域

本发明涉及式I的化合物，其各种衍生物，包含其的组合物，以及它们用于制备治疗或预防受益于调节14-3-3ζ蛋白的疾病的药物的用途，具体地，涉及式I的化合物用于制备治疗或预防癌症的药物的用途。本发明也涉及式I的化合物用于治疗相关的疾病例如癌症的用途。

背景技术

本申请的背景技术描述于以下文献中，将这些文献的全部内容通过参考并入本申请，达到不与本申请中的具体描述不相冲突的程度：

1.Andrews,R.K.,Du,X.,and Berndt,M.C.(2007).The14-3-3zeta-GPIb-IX-V complex as an antiplatelet target.Drug News Perspect20,285-292.

2.Bergamaschi,A.,and Katzenellenbogen,B.S.(2012).Tamoxifen downregulation of miR-451increases14-3-3zeta and promotes breast cancer cell survival and endocrine resistance.Oncogene31,39-47.

3.Bergamaschi,A.,Frasor,J.,Borgen,K.,Stanculescu,A.,Johnson,P.,Rowland,K.,Wiley,E.L.,and Katzenellenbogen,B.S.(2013).14-3-3zeta as a predictor of early time to recurrence and distant metastasis in hormone receptor-positive and-negative breast cancers.Breast Cancer Res Treat137,689-696.

4.Boon,S.S.,and Banks,L.(2013).High-risk human papillomavirus E6oncoproteins interact with14-3-3zeta in a PDZ binding motif-dependent manner.Journal of virology87,1586-1595.

5.Cheah,P.S.,Ramshaw,H.S.,Thomas,P.Q.,Toyo-Oka,K.,Xu,X.,Martin,S.,Coyle,P.,Guthridge,M.A.,Stomski,F.,van den Buuse,M.,Wynshaw-Boris,A.,Lopez,A.F.,and Schwarz,Q.P.(2012).Neurodevelopmental and neuropsychiatric behaviour defects arise from14-3-3zeta deficiency.Mol Psychiatry17,451-466.

6.Choi,J.E.,Hur,W.,Jung,C.K.,Piao,L.S.,Lyoo,K.,Hong,S.W.,Kim,S.W.,Yoon,H.Y.,and Yoon,S.K.(2011).Silencing of14-3-3zeta over-expression in hepatocellular carcinoma inhibits tumor growth and enhances chemosensitivity to cis-diammined dichloridoplatium.Cancer Lett303,99-107.

7.Dai,K.,Bodnar,R.,Berndt,M.C.,and Du,X.(2005).A critical role for14-3-3zeta protein in regulating the VWF binding function of platelet glycoprotein Ib-IX and its therapeutic implications.Blood106,1975-1981.